Dr Lal Pathlabs, Metropolis shares gain on Kotak Equities’ rating upgrades, target price raise

  • Kotak Institutional Equities upgrades Dr Lal Pathlabs to Add and increases fair value to 2,360, while maintaining Reduce rating for Metropolis Healthcare at 1,600. The brokerage sees improved pricing patterns in diagnostics and believes in the leadership team of Dr Lal Pathlabs.

Dhanya Nagasundaram
Published26 Mar 2024, 01:05 PM IST
Following the brokerage's upgrade, Dr Lal Pathlabs share price surged over 5% on Tuesday's session, while Metropolis Healthcare share price rose 2.5%. 
 (PTI Photo) (PTI12_19_2023_000172B)
Following the brokerage’s upgrade, Dr Lal Pathlabs share price surged over 5% on Tuesday’s session, while Metropolis Healthcare share price rose 2.5%. (PTI Photo) (PTI12_19_2023_000172B)(PTI)

After a long stretch of stock underperformance, domestic brokerage Kotak Institutional Equities stated in its most recent report that it has double upgraded Dr Lal Pathlabs from Sell to Add with an increased fair value of 2,360. Given reasonable prices, the brokerage has also increased Metropolis Healthcare's fair value to 1,600, keeping its Reduce rating.

Following the brokerage's upgrade, Dr Lal Pathlabs share price surged over 5% on Tuesday's session, while Metropolis Healthcare share price rose 2.5%. 

Also Read: Multibagger stock: Rategain Travel shares gain for third straight day, up 140% in a year

Over the course of the last year, the brokerage believes that price sanity in diagnostics has increased. The brokerage's most recent price study, which included seven locations, points to continued improvements in pricing patterns.

 A more benign competitive environment allays any serious worries about the structural volume growth and margins of Dr Lal Pathlabs and Metropolis Healthcare, even if the pricing gap between listed heavyweights and online players remains high at 2.0–2.6X.

As compared to its listed peers, the brokerage said that Dr Lal Pathlabs' recent correction—which has dropped by almost 15% in the last month—has been especially severe due to the departure of its CEO. Shankha Banerjee's recent hiring as CEO adds consistency, and the brokerage thinks Dr. Lal Pathlabs has a capable leadership team in place led by MD Dr. Om Manchanda.

Also Read: Correction in midcap, smallcap stocks an entry opportunity; TVS, Zomato best picks among ‘fallen angels’: Emkay Global

"Exciting news! Mint is now on WhatsApp Channels 🚀 Subscribe today by clicking the link and stay updated with the latest financial insights!" Click here!

The brokerage report states that Metropolis Healthcare increased costs throughout KIE's sample test bouquet by 5% qoq. Even though Metropolis Healthcare had previously lowered pricing twice in Delhi NCR, in 4QFY24 it raised prices by almost 14%. The prices for additional incumbents like Vijaya, Thyrocare, and Dr. Lal Pathlabs remained largely unchanged.

Also Read: Beige to offload 2.9% stake in Mankind Pharma through block deals

"Our view of the impact on diagnostics of the recent SC diktat remains similar to hospitals, with the difference being that we expect lower price points in diagnostics to limit any major detrimental regulatory actions.

Compared with a historical 1-year forward P/E premium of 20%+, Dr Lal Pathlabs is now trading at a discount to Metropolis Healthcare. We raise our DCF-based fair value of Dr Lal Pathlabs to 2,360 and Metropolis Healthcare to Rs1,600, largely led by increased growth estimates beyond FY2026E, as we build in lower competitive intensity," said Kotak Institutional Equities in its report.

On the internet, a number of themes resurfaced, with price reductions of 9–20% QoQ by Redcliffe, mFine, and Healthians in 4QFY24. Healthians' costs have now reached an all-time low, according to the brokerage.

However, throughout the last six months, Netmeds has increased costs by almost 35% across the brokerage's sample test bouquet. Prices were also increased qoq by Orange Health and Tata 1mg, among other online marketplaces. With one exception—Delhi—Healthians and Tata 1mg continue to be the most active online players, while Netmeds continues to lead the field, according to the report.

Also Read: Coal India share price gains after Emkay Global initiates coverage with a ‘Buy’ call, sees 27% upside

Disclaimer: The views and recommendations above are those of individual analysts, experts and broking companies, not of Mint. We advise investors to check with certified experts before making any investment decisions.

Catch all the Business News, Market News, Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.MoreLess

News in Numbers

Numbers that help you understand news better
₹68,885 Cr



₹6.7 T

$240.5 M

$459 M

$3 B

₹588.25 Cr

₹20,000 Cr

7.93 Cr

₹8,943 Cr


20 Yrs

First Published:26 Mar 2024, 01:05 PM IST
HomeMarketsStock MarketsDr Lal Pathlabs, Metropolis shares gain on Kotak Equities’ rating upgrades, target price raise

Most Active Stocks

Bharat Electronics

03:59 PM | 18 JUL 2024
-12.85 (-3.94%)

Oil & Natural Gas Corporation

03:59 PM | 18 JUL 2024
8.8 (2.73%)

Zee Entertainment Enterprises

03:59 PM | 18 JUL 2024
-13 (-8.36%)

Tata Steel

03:56 PM | 18 JUL 2024
-0.7 (-0.42%)
More Active Stocks

Market Snapshot

  • Top Gainers
  • Top Losers
  • 52 Week High

India Cements

03:54 PM | 18 JUL 2024
21.7 (6.72%)


03:59 PM | 18 JUL 2024
4.27 (4.86%)

Endurance Technologies

03:29 PM | 18 JUL 2024
102.4 (3.97%)

Gillette India

03:29 PM | 18 JUL 2024
275 (3.56%)
More from Top Gainers

Recommended For You

    More Recommendations

    Gold Prices

    • 24K
    • 22K

    Fuel Price

    • Petrol
    • Diesel
    New Delhi
    HomeMarketsPremiumInstant LoanBudget